- Home
- QSI vs KZIA Comparison
QSI vs KZIA Comparison
Compare QSI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | KZIA |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 186.7M |
| IPO Year | 2020 | 2002 |
Fundamental Metrics
Financial Performance| Metric | QSI | KZIA |
|---|---|---|
| Price | $0.76 | $10.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.00 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 1.7M | 329.1K |
| Earning Date | 05-07-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,436,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $618.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $4.86 |
| 52 Week High | $3.10 | $17.40 |
Technical Indicators
Market Signals| Indicator | QSI | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 40.08 |
| Support Level | $0.70 | $10.59 |
| Resistance Level | $0.79 | $14.85 |
| Average True Range (ATR) | 0.03 | 0.82 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 41.72 | 14.69 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.